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Background: Odontogenic myxoma (OM) is a benign intraosseous neoplasm that exhibits local aggressiveness 
and high recurrence rates. Osteoclastogenesis is an important phenomenon in the tumor growth of maxillary neo-
plasms. RANK (Receptor Activator of Nuclear Factor κappa B) is the signaling receptor of RANK-L (Receptor 
activator of nuclear factor kappa-Β ligand) that activates the osteoclasts. OPG (osteoprotegerin) is a decoy recep-
tor for RANK-L that inhibits pro-osteoclastogenesis. The RANK / RANK-L / OPG system participates in the 
regulation of osteolytic activity under normal conditions, and its alteration has been associated with greater bone 
destruction, and also with tumor growth.
Objectives: To analyze the immunohistochemical expression of OPG, RANK and RANK-L proteins in odonto-
genic myxomas (OMs) and their relationship with the tumor size.
Material and Methods: Eighteen OMs, 4 small (<3 cm) and 14 large (> 3cm) and 18 dental follicles (DF) that were 
included as control were studied by means of standard immunohistochemical procedure with RANK, RANK-L 
and OPG antibodies. For the evaluation, 5 fields (40x) of representative areas of OM and DF were selected where 
the expression of each antibody was determined. Descriptive and comparative statistical analyses were performed 
with the obtained data.
Results: There are significant differences in the expression of RANK in OM samples as compared to DF (p = 
0.022) and among the OMSs and OMLs (p = 0.032). Also a strong association is recognized in the expression of 
RANK-L and OPG in OM samples.
doi:10.4317/medoral.22372
http://dx.doi.org/doi:10.4317/medoral.22372
González-Galván MC, Mosqueda-Taylor A, Bologna-Molina R, Se-
tien-Olarra A, Marichalar-Mendia X, Aguirre-Urizar JM. Evaluation 
of the osteoclastogenic process associated with RANK / RANK-L / OPG 
in odontogenic myxomas. Med Oral Patol Oral Cir Bucal. 2018 May 1;23 
(3):e315-9.   
http://www.medicinaoral.com/medoralfree01/v23i3/medoralv23i3p315.pdf
Article Number: 22372         http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
Med Oral Patol Oral Cir Bucal. 2018 May 1;23 (3):e315-9.                                                                                          Osteoclastogenic process RANK / RANK-L / OPG in odontogenic myxoma
e316
Introduction
Odontogenic myxoma (OM) is a benign intraosseous neo-
plasm of the jaws, which exhibits local aggressiveness and 
high recurrence rates (1). Its frequency ranges between 
2.2% and 17.7% of all odontogenic tumors (2-12).
It is characterized microscopically by a monotonous 
hypocellular proliferation of spindle-shaped or stellate 
cells embedded in an abundant myxoid extracellular 
matrix, with little amount of collagen, although some 
cases may show a greater amount and are called mixo-
fibromas (13-15).
The treatment of choice is conservative or radical surgi-
cal excision, depending on the size and location of the 
tumor (16). Radiological long-term follow-up is man-
datory, as recurrence has been reported up to 15 years 
after surgery (1).
RANK (receptor activator of nuclear factor kappa B) is 
a member of the family of tumor necrosis factor recep-
tors, and is the signaling receptor of RANK-L (receptor 
ligand activator for nuclear factor κappa B) (17). The 
RANK-L homotrimeric protein is typically bound to 
the membrane of osteoblastic cells and its binding to 
RANK stimulates the activation of osteoclasts (17,18). 
Osteoprotegerin (OPG) is a decoy receptor of RANK-L 
that inhibits pro-osteoclastogenesis through the interac-
tion of RANK-L and RANK, thereby inhibiting bone 
resorption (17). 
The RANK / RANK-L / OPG system participates in the 
regulation of osteolytic activity under normal condi-
tions, and its alteration is associated with various patho-
logic conditions, including bone destruction associated 
to tumor growth (19). The interaction between RANK 
and RANK-L plays a critical role in the production, dif-
ferentiation and activation of osteoclasts, which leads to 
bone resorption (20,21).
The purpose of this study was to analyze and com-
pare the immunohistochemical expression of RANK, 
RANK-L and OPG proteins in odontogenic myxoma 
and its relationship with tumor size.
Material and Methods
Tissue samples from 18 inflammation-free odontogenic 
myxomas (10 women and 8 men, mean age 32.83 years, 
range 10 - 53) and 18 inflammation-free dental follicles 
(9 women and 9 men, mean age 14. 4 years, range 9 - 
22) diagnosed at the Oral Pathology Laboratory of the 
Universidad Autonoma Metropolitana Xochimilco and 
a private Oral Pathology Service in Mexico City were 
included in the present study.
This study was approved by the Division of Biological 
and Health Sciences of the Universidad Autonoma Met-
ropolitana Xochimilco (Mexico).
The size of the OMs included in this study was obtained 
from radiographic interpretation stated in the clinical 
files. OM samples were classified as small myxomas 
(OMS) when these were up to 3 cm (N = 4), and large 
myxomas (OML) when greater than 3 cm (N = 13) in its 
larger dimension. No data on the size of the tumor could 
be obtained from one of the odontogenic myxomas.
The histopathological diagnosis in each case was con-
firmed in sections stained with H&E and was based on 
microscopic criteria described in the most recent WHO 
Histological Classification of Tumors of the Head and 
Neck (22).
Two microns sections were obtained from each paraf-
fin block, which were subsequently dewaxed, hydrated 
and treated with 0.1 mol / L sodium citrate (pH 6.2) to 
expose the antigenic epitopes. The endogenous per-
oxidases were blocked with 0.9% hydrogen peroxide. 
Incubation of the primary antibody was carried out in 
humidity chambers (Sequenza ™ Slide Rack), with a 
1: 150 dilution of the OPG polyclonal antibody (Gene 
Tex®, USA, 45 minutes); 1: 500 of the RANK polyclonal 
antibody (Gene Tex®, USA, 45 minutes) and 1: 800 of 
the RANK-L polyclonal antibody (Gene Tex®, USA, 45 
minutes). Antibody dilutions were carried out with the 
diluent S2022 (DAKO®, Carpintería, Ca, USA). The 
reaction was visualized with the Mouse Rabil Immu-
nodetector system (BioSB ®, Santa Bárbara, Ca, USA), 
and revealed with 3.3 diaminobenzidine-hydrochloride 
(DAB) producing a brown precipitate. The contrast of 
the sections was performed with Gill’s hematoxylin and 
the assembly with a permanent medium (Eukitt®). Pos-
itive and negative controls were made for each antibody.
A qualitative and semiquantitative assessment of the 
histological and immunohistochemical aspects was 
performed with an Olympus® microscope (CX31), ana-
lyzing 5 fields of 40x in each case, using the Image J® 
program to count cells. The assessment of the immu-
nohistochemical expression was carried out by 3 oral 
pathologists in an individualized manner and subse-
quently a common consensus was reached. The evalu-
ation criteria were based on previous studies (18,19,23).
The rack proposed by Bologna-Molina et al. (24) was 
used for the analysis of the immunohistochemical ex-
pression. Then, with a digital camera (Olympus® CX 
31) five microphotographs of the most representative 
areas were taken at 40x. Subsequently, a 6x6 rack was 
Conclusions: Activation of the RANK / RANK-L / OPG triad seems to be involved in the mechanisms of bone bal-
ance and destruction, as well as associated with tumor growth in odontogenic myxomas.
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placed on each photograph. In each image, the start of 
cell counting was made from the upper left frame and 
culminated in the upper right margin, following the 
same order (Fig. 1). In this way, the manual counting of 
the number of positive and negative cells in each box of 
the rack was made, helped by the Image J® software.
Statistical analyzes carried out in this study, descrip-
tive and comparative, were performed using SPSS v15.0 
(SPSS Inc®, Chicago, ILL, USA). The examiners were 
standardized and a Kappa index of 0.88 was obtained. 
The comparison of the means of the immunohistochem-
ical marker was performed with the Mann-Whitney U-
test and the Kruskal-Wallis test, and p-values <0.05 
were considered statistically significant. 
Fig. 1: Method employed of the positive cell counting (40×).
Results
Table 1 shows the results found in relation to the im-
munohistochemical markers analyzed. When compared 
to DF, only RANK displayed a significant expression 
in OM samples (p = 0.022). Specifically, RANK shows 
lower expression in the OM group. Additionally, the 
OPG marker is close to the statistically significant dif-
ference among OM and FD groups.
When analyzing the expression levels of the 3 selected 
markers, we found statistically significant differences 
in RANK marker (p = 0.032), observing a lower mean 
expression in the OML group in relation to the OMS 
group. When comparing the levels of expression of the 
other two markers, RANK-L and OPG, we did not find 
statistically significant differences (p = 0.202 and p = 
0.296 respectively), however these two markers have 
similar patterns of expression as in RANK, i.e., OML 
samples presented a higher expression.
Table 2 shows the correlation between the different 
markers. In odontogenic myxomas, there is a strong cor-
relation among RANK-L and OPG markers (p = 0.002) 
and not so strong among RANK and OPG markers (p 
= 0.021). On the other hand, there was not a statistically 
significant correlation among RANK and RANK-L 
markers (p = 0.069).
Finally, in relation to dental follicles, the 3 ratios, 
RANK-L / OPG (p = 0.031) RANK / RANK-L (p = 
0.002) and RANK / OPG (p = 0.008) displayed statisti-
cally significant correlations.
Discussion
Previous studies (18,19,23,25) have shown that the 
Lesion 
type
N Mean of positive cells
RANK RANK-L OPG
Mean (SD) p value Mean (SD) p value Mean (SD) p value
OM 18 17.25 (16.39) 0.022a 20.70 (21.02) 0.192ª 60.32 (29.55) 0.064a
OMS 4 38.07 (17.76) 0.032b 32.29 (21.32) 0.202b 77.01 (3.45) 0.296b
OML 13 10.25 (9.98) 16.03 (20.66) 55.04 (33.34)
DF 18 35.55 (22.84)  30.77 (23.48)  75.13 (17.35)  
Table 1: Average expression of RANK, RANK-L and OPG in odontogenic myxomas (OM) and dental follicles (DF).
OM: Odontogenic myxoma; OMS: Small odontogenic myxoma; OML: Large odontogenic myxoma; DF: Dental follicles; a: OM vs DF; b: OMS 
vs OML.
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 RANK-L OPG p value RANK RANK-L p value RANK 
OPG
p value
OM 0.689 p= 0.002 0.438 p= 0.069 0.539 p= 0.021
DF 0.509 p= 0.031 0.670 p= 0.002 0.605 p=0.008
Table 2: Spearman’s Correlation Test on the Expression of RANK-RANK-L-OPG in odontogeic myxomas (OM) and  dental follicles (DF).
OM: Odontogenic myxoma; DF: Dental follicles.
RANK / RANK-L / OPG system is abnormally regu-
lated in several osteolytic diseases, including neoplastic 
and non-neoplastic odontogenic lesions, where a high-
er expression of RANK-L or a decrease in OPG lev-
els seem to play an important role in bone destruction 
(19,21,25). The process of tumor osteolysis has been 
associated with changes in the levels of RANK-L and 
OPG in multiple myeloma, osteosarcoma, osteoblastic 
metastasis of prostate carcinoma, giant cell lesions, and 
interestingly, in some odontogenic tumors, such as am-
eloblastoma, odontogenic keratocyst and calcifying epi-
thelial odontogenic tumor (18,23,25).
In 2008 Andrade et al. carried out the first study that 
suggests that the alteration in the RANK / RANK-L / 
OPG signaling pathway could be related to the bone loss 
that occurs in various odontogenic tumors (23). Among 
the lesions studied, 7 OMs were included, 4 of which 
exhibited a greater expression of RANK-L in relation 
to OPG. Our results were contrary to this, observing a 
greater positivity in OPG (94.4%) in relation to RANK-
L (66.6%). There are some points that need to be taken 
into consideration in order to explain these differences; 
first, these dissimilarities could be related to the greater 
number of cases in our study and their analysis accord-
ing to different sizes, as well as differences in the meth-
odology employed, which are fundamental elements in 
these investigations.
On the other hand, although we did not find significant 
differences in relation to the size of the lesions, it is 
important to mention that in OMS there was a smaller 
expression of OPG and RANK-L. These data could sug-
gest that while increasing the size of OMs, osteoclasto-
genic activity tend to increase, which could be related 
to clinical aspects, since OM is a neoplasm that grows 
more slowly through bone tissue as compared to other 
locally infiltrating tumors. In addition, it could be sug-
gested that the differences observed in the size of the 
sample, the stage (size) of the lesions at the time of the 
diagnosis and the presence of inflammation present in 
previous studies (19,23) could also help to explain the 
disparities observed in relation to our findings.
Moreover, we observed in our study that DF samples 
have a higher average of positive cells for RANK, 
RANK-L and OPG than OM samples, but RANK was 
the only marker that showed statistically significant dif-
ferences (p˂0.05), independently of the size of the OMs. 
In addition, we have found a strong association between 
RANK-L and OPG in OM samples, and among RANK 
/ RANK-L in DF samples. These findings suggest that 
the modification produced in this pathway would be one 
of the mechanisms by which this benign but aggressive 
odontogenic neoplasm can grow and invade the adja-
cent tissue as it reaches a larger size.
In this regard, our findings and those of Andrade et al. 
(23) indicate that most of the odontogenic tumors pres-
ent variations among RANK-L and OPG expression, 
possibly dependent on the type of tumor, mechanisms 
of growth, and size, which has been interpreted as ac-
tive and inactive stages of tumor growth and stages of 
interference with tumor osteolysis (19).
In order to compare among those studies that have evalu-
ated these markers, it is necessary to have a standardized 
method that is objective and reproducible in all cases, 
since the differences found in some studies (23,26,27) 
could be due to different evaluation criteria, sampling, 
technical conditions or tissue preservation. For this rea-
son, in our study we have used the method proposed by 
Bologna-Molina et al. (24), through which the cell count-
ing could be performed in an objective manner. The stan-
dardization of this method could be of great relevance for 
studies aimed to find new therapeutic strategies to reduce 
the size or growth of this type of lesion.
Based on the fact that Qian et al. (26) found that OPG 
suppresses both, osteoclastogenesis induced by amelo-
blastoma and bone resorption caused by osteoclasts, De 
Matos et al. (27) have suggested that OPG could be used 
as therapeutic treatment of ameloblastoma in the future 
to stop bone loss and thus, minimize the extent of bone 
destruction before surgical management (23).
Different studies performed by our group (14,28,29) 
have shown that the growth of the odontogenic myxoma 
is the product of a complex multifactorial process in 
which cell proliferation and angiogenesis are involved 
mainly in the early stages. With the present results, we 
suggest that the growth of these neoplasms can also be 
related with the production and performance of differ-
ent mechanisms related with the RANK / RANK-L 
/ OPG system. The increase of the tumor size would 
modify the production of these proteins, modifying 
their growth capacity.
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In summary, our results suggest that the RANK / 
RANK-L / OPG triad may be involved in the mecha-
nisms of bone balance and destruction of odontogenic 
myxomas. These data also suggest that the modification 
produced in this signaling pathway would be one of the 
main mechanisms by which this odontogenic neoplasm 
grows and invades the adjacent tissues. 
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